Does the media refer more to BMRN or ALNY?

In the previous week, Alnylam Pharmaceuticals had 24 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 30 mentions for Alnylam Pharmaceuticals and 6 mentions for BioMarin Pharmaceutical. Alnylam Pharmaceuticals' average media sentiment score of 1.12 beat BioMarin Pharmaceutical's score of 0.64 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 22 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BIIB or BMRN?

In the previous week, Biogen had 30 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 36 mentions for Biogen and 6 mentions for BioMarin Pharmaceutical. Biogen's average media sentiment score of 0.83 beat BioMarin Pharmaceutical's score of 0.64 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 18 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BMRN or UTHR?

In the previous week, United Therapeutics had 19 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 25 mentions for United Therapeutics and 6 mentions for BioMarin Pharmaceutical. United Therapeutics' average media sentiment score of 0.84 beat BioMarin Pharmaceutical's score of 0.64 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 16 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INCY or BMRN?

In the previous week, Incyte had 28 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 34 mentions for Incyte and 6 mentions for BioMarin Pharmaceutical. Incyte's average media sentiment score of 0.69 beat BioMarin Pharmaceutical's score of 0.64 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 18 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BMRN or NBIX?

In the previous week, Neurocrine Biosciences had 8 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 14 mentions for Neurocrine Biosciences and 6 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.64 beat Neurocrine Biosciences' score of 0.53 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioMarin Pharmaceutical (BMRN) Competitors

$56.17 -1.74 (-3.00%)

Closing price 04:00 PM Eastern

Extended Trading

$56.66 +0.49 (+0.87%)

As of 07:49 PM Eastern

Compare

BMRN vs. ALNY, BIIB, UTHR, INCY, and NBIX

Should you buy BioMarin Pharmaceutical stock or one of its competitors? MarketBeat compares BioMarin Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

BioMarin Pharmaceutical has higher earnings, but lower revenue than Alnylam Pharmaceuticals. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.37	$348.90M	$1.37	41.00
Alnylam Pharmaceuticals	$3.71B	10.47	$313.75M	$3.66	79.57

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.9% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alnylam Pharmaceuticals has a net margin of 11.72% compared to BioMarin Pharmaceutical's net margin of 8.29%. Alnylam Pharmaceuticals' return on equity of 85.76% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	8.29%	6.50%	5.07%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

BioMarin Pharmaceutical has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

In the previous week, Alnylam Pharmaceuticals had 24 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 30 mentions for Alnylam Pharmaceuticals and 6 mentions for BioMarin Pharmaceutical. Alnylam Pharmaceuticals' average media sentiment score of 1.12 beat BioMarin Pharmaceutical's score of 0.64 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	22 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical currently has a consensus price target of $88.67, indicating a potential upside of 57.85%. Alnylam Pharmaceuticals has a consensus price target of $463.13, indicating a potential upside of 59.03%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.79
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

Summary

Alnylam Pharmaceuticals beats BioMarin Pharmaceutical on 14 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Biogen?

Biogen (NASDAQ:BIIB) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Biogen currently has a consensus target price of $217.26, indicating a potential upside of 11.85%. BioMarin Pharmaceutical has a consensus target price of $88.67, indicating a potential upside of 57.85%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	12 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.55
BioMarin Pharmaceutical	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.79

Biogen has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

In the previous week, Biogen had 30 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 36 mentions for Biogen and 6 mentions for BioMarin Pharmaceutical. Biogen's average media sentiment score of 0.83 beat BioMarin Pharmaceutical's score of 0.64 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	18 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.90	$1.29B	$9.32	20.84
BioMarin Pharmaceutical	$3.22B	3.37	$348.90M	$1.37	41.00

Biogen has a net margin of 13.81% compared to BioMarin Pharmaceutical's net margin of 8.29%. Biogen's return on equity of 12.83% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
BioMarin Pharmaceutical	8.29%	6.50%	5.07%

87.9% of Biogen shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Biogen and BioMarin Pharmaceutical tied by winning 8 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to United Therapeutics?

BioMarin Pharmaceutical (NASDAQ:BMRN) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

BioMarin Pharmaceutical has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

United Therapeutics has a net margin of 40.62% compared to BioMarin Pharmaceutical's net margin of 8.29%. United Therapeutics' return on equity of 19.24% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	8.29%	6.50%	5.07%
United Therapeutics	40.62%	19.24%	17.25%

BioMarin Pharmaceutical currently has a consensus price target of $88.67, suggesting a potential upside of 57.85%. United Therapeutics has a consensus price target of $619.42, suggesting a potential upside of 13.84%. Given BioMarin Pharmaceutical's higher probable upside, research analysts plainly believe BioMarin Pharmaceutical is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.79
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has lower revenue, but higher earnings than BioMarin Pharmaceutical. United Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.37	$348.90M	$1.37	41.00
United Therapeutics	$3.17B	7.29	$1.33B	$27.09	20.08

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 0.9% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, United Therapeutics had 19 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 25 mentions for United Therapeutics and 6 mentions for BioMarin Pharmaceutical. United Therapeutics' average media sentiment score of 0.84 beat BioMarin Pharmaceutical's score of 0.64 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	16 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

United Therapeutics beats BioMarin Pharmaceutical on 11 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Incyte?

Incyte (NASDAQ:INCY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Incyte has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Incyte has higher revenue and earnings than BioMarin Pharmaceutical. Incyte is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.10	$1.29B	$7.08	14.89
BioMarin Pharmaceutical	$3.22B	3.37	$348.90M	$1.37	41.00

In the previous week, Incyte had 28 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 34 mentions for Incyte and 6 mentions for BioMarin Pharmaceutical. Incyte's average media sentiment score of 0.69 beat BioMarin Pharmaceutical's score of 0.64 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	18 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte presently has a consensus target price of $105.10, suggesting a potential downside of 0.28%. BioMarin Pharmaceutical has a consensus target price of $88.67, suggesting a potential upside of 57.85%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	13 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
BioMarin Pharmaceutical	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.79

97.0% of Incyte shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 16.2% of Incyte shares are owned by insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Incyte has a net margin of 26.71% compared to BioMarin Pharmaceutical's net margin of 8.29%. Incyte's return on equity of 26.66% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
BioMarin Pharmaceutical	8.29%	6.50%	5.07%

Summary

Incyte beats BioMarin Pharmaceutical on 11 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Neurocrine Biosciences?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Neurocrine Biosciences has a net margin of 21.55% compared to BioMarin Pharmaceutical's net margin of 8.29%. Neurocrine Biosciences' return on equity of 19.79% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	8.29%	6.50%	5.07%
Neurocrine Biosciences	21.55%	19.79%	13.82%

BioMarin Pharmaceutical has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 0.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Neurocrine Biosciences had 8 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 14 mentions for Neurocrine Biosciences and 6 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.64 beat Neurocrine Biosciences' score of 0.53 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical currently has a consensus price target of $88.67, suggesting a potential upside of 57.85%. Neurocrine Biosciences has a consensus price target of $187.52, suggesting a potential upside of 16.58%. Given BioMarin Pharmaceutical's higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.79
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.87

Neurocrine Biosciences has lower revenue, but higher earnings than BioMarin Pharmaceutical. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.37	$348.90M	$1.37	41.00
Neurocrine Biosciences	$2.86B	5.65	$478.60M	$6.49	24.79

Summary

Neurocrine Biosciences beats BioMarin Pharmaceutical on 11 of the 17 factors compared between the two stocks.

Get BioMarin Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRN vs. The Competition

Export

Metric	BioMarin Pharmaceutical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.19B	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	41.00	18.83	24.65	23.63
Price / Sales	3.37	290.84	500.87	105.21
Price / Cash	20.30	120.20	43.05	54.72
Price / Book	1.77	8.00	10.43	6.70
Net Income	$348.90M	$23.89M	$3.56B	$337.26M
7 Day Performance	2.76%	-3.49%	-1.39%	-1.41%
1 Month Performance	3.90%	1.03%	0.86%	1.15%
1 Year Performance	-2.28%	34.39%	19.42%	22.61%

BioMarin Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMRN BioMarin Pharmaceutical	4.6483 of 5 stars	$56.17 -3.0%	$88.67 +57.9%	+1.8%	$11.19B	$3.22B	41.00	3,221
ALNY Alnylam Pharmaceuticals	4.5942 of 5 stars	$305.22 +0.5%	$463.13 +51.7%	-2.1%	$40.73B	$3.71B	83.35	2,770	Positive News
BIIB Biogen	3.7227 of 5 stars	$199.57 +1.6%	$215.81 +8.1%	+48.4%	$29.46B	$9.89B	21.41	7,500	Trending News Analyst Upgrade
UTHR United Therapeutics	4.3002 of 5 stars	$549.69 +0.4%	$619.42 +12.7%	+68.4%	$23.33B	$3.17B	20.29	1,400	Insider Trade
INCY Incyte	3.4168 of 5 stars	$104.55 +3.3%	$104.00 -0.5%	+47.7%	$20.87B	$5.36B	14.75	2,844	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMRN) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Summary

How does BioMarin Pharmaceutical compare to United Therapeutics?

Summary

How does BioMarin Pharmaceutical compare to Incyte?

Summary

How does BioMarin Pharmaceutical compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Which has better valuation and earnings, BMRN or ALNY?

Do insiders & institutionals believe in BMRN or ALNY?

Is BMRN or ALNY more profitable?

Which has more risk & volatility, BMRN or ALNY?

Does the media refer more to BMRN or ALNY?

Do analysts prefer BMRN or ALNY?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Do analysts prefer BIIB or BMRN?

Which has more risk and volatility, BIIB or BMRN?

Does the media prefer BIIB or BMRN?

Which has preferable earnings & valuation, BIIB or BMRN?

Is BIIB or BMRN more profitable?

Do institutionals and insiders believe in BIIB or BMRN?

Summary

How does BioMarin Pharmaceutical compare to United Therapeutics?

Which has more risk & volatility, BMRN or UTHR?

Is BMRN or UTHR more profitable?

Do analysts prefer BMRN or UTHR?

Which has higher earnings & valuation, BMRN or UTHR?

Do institutionals & insiders hold more shares of BMRN or UTHR?

Does the media refer more to BMRN or UTHR?

Summary

How does BioMarin Pharmaceutical compare to Incyte?

Which has more risk & volatility, INCY or BMRN?

Which has higher valuation and earnings, INCY or BMRN?

Does the media favor INCY or BMRN?

Do analysts recommend INCY or BMRN?

Do institutionals and insiders hold more shares of INCY or BMRN?

Is INCY or BMRN more profitable?

Summary

How does BioMarin Pharmaceutical compare to Neurocrine Biosciences?

Is BMRN or NBIX more profitable?

Which has more volatility & risk, BMRN or NBIX?

Do institutionals & insiders hold more shares of BMRN or NBIX?

Does the media favor BMRN or NBIX?

Do analysts recommend BMRN or NBIX?

Which has preferable earnings & valuation, BMRN or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools